Neben S, Hellman S, Montgomery M, Ferrara J, Mauch P
Department of Radiation Oncology, Harvard Medical School, Boston, MA 02115.
Exp Hematol. 1993 Jan;21(1):156-62.
High-dose chemotherapy and/or total body irradiation followed by autologous bone marrow rescue has improved the survival of patients with a variety of malignancies. Candidates for autologous bone marrow transplantation (ABMT) often have received prior exposure to cytotoxic agents, some of which may damage primitive stem cells. We have developed an in vivo murine model to evaluate the effects of a number of individual cytotoxic agents on the ability of syngeneic donor marrow to provide long-term hematopoiesis in recipients following high-dose total body irradiation. Marrow was experimentally obtained by giving donor mice 6 weekly injections of saline, cytosine arabinoside, cyclophosphamide, cisplatin, 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), or busulfan, drugs known to have differing effects on primitive hematopoietic stem cells. After time to allow recovery of marrow and peripheral blood counts, 1 x 10(7) marrow cells from these mice were transplanted into lethally irradiated syngeneic recipients. Five to 6 months after marrow transplantation, the quality of long-term hematopoietic recovery was measured by WBC counts, marrow cellularity, CFU-S content, and determinations of stem cell self-renewal. Abnormalities were noted with the use of donor marrow exposed to all cytotoxic agents. Recipients of marrow previously exposed to cytosine arabinoside, an agent that spares the most primitive stem cells, were the least affected. Recipients of marrow previously exposed to busulfan, an agent known to damage primitive stem cells, were most affected with a decrease in peripheral blood counts, marrow cellularity, stem cell content, self-renewal capacity, and long-term survival. A decrease in hematopoietic stem cell self-renewal was seen in recipients of marrow previously exposed to cyclophosphamide, cisplatin, and BCNU even when marrow cellularity and CFU-S content were normal. These data suggest that the capacity of syngeneic donor marrow to provide long-term hematopoiesis in lethally irradiated recipients is dependent on its donor marrow primitive stem cell content. Long-term hematopoiesis may be severely compromised in recipients of donor stem cells previously exposed to cytotoxic agents which damage primitive stem cells.
大剂量化疗和/或全身照射后进行自体骨髓挽救已提高了多种恶性肿瘤患者的生存率。自体骨髓移植(ABMT)的候选者通常先前已接触过细胞毒性药物,其中一些可能会损害原始干细胞。我们建立了一种体内小鼠模型,以评估多种单独的细胞毒性药物对同基因供体骨髓在大剂量全身照射后为受体提供长期造血功能的能力的影响。通过每周给供体小鼠注射6次生理盐水、阿糖胞苷、环磷酰胺、顺铂、1,3-双(2-氯乙基)-1-亚硝基脲(BCNU)或白消安来实验性获取骨髓,这些药物对原始造血干细胞具有不同的作用。在给予时间使骨髓和外周血细胞计数恢复后,将来自这些小鼠的1×10⁷个骨髓细胞移植到接受致死性照射的同基因受体中。骨髓移植后5至6个月,通过白细胞计数、骨髓细胞密度、CFU-S含量以及干细胞自我更新的测定来衡量长期造血恢复的质量。使用暴露于所有细胞毒性药物的供体骨髓时均发现了异常。先前暴露于阿糖胞苷(一种对最原始干细胞有保护作用的药物)的骨髓受体受影响最小。先前暴露于白消安(一种已知会损害原始干细胞的药物)的骨髓受体受影响最大,外周血细胞计数、骨髓细胞密度、干细胞含量、自我更新能力和长期生存率均下降。即使骨髓细胞密度和CFU-S含量正常,先前暴露于环磷酰胺、顺铂和BCNU的骨髓受体中也出现了造血干细胞自我更新的下降。这些数据表明,同基因供体骨髓在致死性照射受体中提供长期造血功能的能力取决于其供体骨髓原始干细胞的含量。先前暴露于损害原始干细胞的细胞毒性药物的供体干细胞受体的长期造血功能可能会受到严重损害。